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Abstract: Aerobic  metabolism occurs in a background of oxygen radicals and reactive 
oxygen species (ROS) that originate from the incomplete reduction of molecular oxygen   
in  electron transfer  reactions.  The  essential  role  of  aerobic  metabolism,  the  generation   
and  consumption  of  ATP  and  other  high  energy  phosphates,  sustains  a  balance  of 
approximately 3000 essential human metabolites that serve not only as nutrients, but also 
as antioxidants, neurotransmitters, osmolytes, and participants in ligand-based and other 
cellular  signaling.  In  hypoxia,  ischemia,  and  oxidative  stress,  where  pathological 
circumstances cause oxygen radicals to form at a rate greater than is possible for their 
consumption, changes in the composition of metabolite ensembles, or metabolomes, can be 
associated with physiological changes. Metabolomics and metabonomics are a scientific 
disciplines that focuse on quantifying dynamic metabolome responses, using multivariate 
analytical  approaches  derived  from  methods  within  genomics,  a  discipline  that 
consolidated innovative analysis techniques for situations where the number of biomarkers 
(metabolites in our case) greatly exceeds the number of subjects. This review focuses on 
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the  behavior  of  cytosolic,  mitochondrial,  and  redox  metabolites  in  ameliorating  or 
exacerbating  oxidative  stress.  After  reviewing  work  regarding  a  small  number  of 
metabolites—pyruvate, ethyl pyruvate, and fructose-1,6-bisphosphate—whose exogenous 
administration was found to ameliorate oxidative stress, a subsequent section reviews basic 
multivariate statistical methods common in metabolomics research, and their application in 
human and preclinical studies emphasizing oxidative stress. Particular attention is paid to 
new NMR spectroscopy methods in metabolomics and metabonomics. Because complex 
relationships connect oxidative stress to so many physiological processes, studies  from 
different disciplines were reviewed. All, however, shared the common goal of ultimately 
developing “omics”-based, diagnostic tests to help influence therapies. 
Keywords:  metabolomics;  metabonomics;  oxidative  stress;  NMR;  proteomics; 
transcriptionomics;  multivariate  analysis;  Principal  Component  Analysis;  targeted 
profiling; chemometrics; brain; liver; kidney; heart 
 
1. Introduction 
The innovations produced and inspired by the Human Genome Project included new approaches to 
analyzing problems where the number of people or organisms in a study is enormously smaller than 
number of biomarkers—genes in the case of genomics, proteins in the case of proteomics, transcription 
factors  in  the  case  of  transcriptionomics,  and  metabolites  in  the  case  of  metabolomics  and 
metabonomics.  The  new  consolidation  of  fundamental  intellectual  concepts  common  to  statistical 
analyses  in all of these  multivariate disciplines has been given the  label of  “omics”. Advances  in 
measurement technologies that have occurred in parallel in each of the “omics” specialties have led to 
an explosion of advances and publications. In metabolic studies the tradition has gone from focusing 
on a limited number of key metabolites having principal roles in the situation under investigation, to 
focusing on a metabolomics or metabonomics approach. Because large numbers of accurate metabolite 
quantifications  can  now  be  made  in  many  instances,  it  is  possible  that  aggregates  of  metabolite 
changes  might  reveal  mechanisms  or  key  metabolic  reactions  that  are  not  discernable  in 
hypothesis-based  studies  of  limited  subsets.  Numerous  review  papers  have  provided  overviews of 
metabolomics and metabonomics from different mechanistic and physiological perspectives [1–13]. 
None of the reviews, however, have specifically emphasized the complex area of oxidative stress. Our 
research  focus,  which  is  the  use  of  NMR  technologies  for  understanding  healthy  and  unhealthy 
neurophysiological situations involving oxidative stress, has motivated us to review the metabolomics 
and metabonomics literature with this focus. In this paper we present our views of the most important 
conceptual and practical points about oxidative stress and metabolomics and metabonomics, and then 
discuss important recent advances and studies, going from studies which emphasized a limited number 
of metabolites to studies that emphasized the behavior of entire metabolomes. Int. J. Mol. Sci. 2011, 12  6471 
 
2. Results and Discussion 
2.1. What is Metabolomics? What is Metabonomics? 
The  ensemble  of  metabolites  in  an  organism  is  known  as  its  metabolome.  In  1999  the  term 
metabonomics  was  devised  to  describe  “the  multiparametric,  quantitative  study  of  dynamic 
metabolome  responses  in  living  systems  to  physiological  and  pathophysiological  stimulation  or 
genetic modification” [14–16]. However, a competing term appeared in 2001: metabolomics, that was 
generally  defined  as:  the  “comprehensive  and  quantitative  analysis  of  all  metabolites…”  [16,17]. 
Various publications have made distinctions between the two words so as to prescribe and proscribe 
situations where each term should  be used. However, dictionaries created by  lexicographers since 
Samuel Johnson, who wrote in an 18th century in a preface that “no dictionary can embalm language, 
and secure it from corruption and decay”, are at least in part descriptive, accepting as meanings those 
intended in daily use by people. Many papers have used the terms metabolomics and metabonomics 
interchangeably,  despite  assertions  that  such  should  not  be  done  [16].  We  are  using  the  word 
metabolomics throughout this review to include what is in the metabonomics definition given above.   
As  with  genomics,  proteomics,  and  transcriptionomics,  the  mathematics  within  metabolomics 
developed from the Human Genome Project, a massive research effort between the mid-1990s and 
2003  that  produced  refined  multivariate  analyses  for  situations  where  the  number  of  biomarkers 
greatly exceeds the number of subjects. Although one can obtain data from as many as hundreds or 
thousands of humans or animals, the number of human genes is estimated to be 30,000 to 40,000, 
while  the  number  of  essential  human  metabolites  is  estimated  as  “more  than  3,000”  [18],  with 
additional,  complex  metabolites  possible  from  combinations  of  those  essential.  The  general 
multivariate  approaches,  which  became  known  as  “the  omics”,  serve  as  key  tools  for  elucidating 
biological  mechanisms,  screening  for  disease,  stratifying  patient  risks,  and  ultimately  shaping  the 
individualization of medical therapies. In comparison to quantifications of transcription factors and 
proteins,  metabolic quantifications  more accurately reflect biological endpoints. Although the term 
“metabolomics”  was  used  occasionally  prior  to  1995,  the  high  output  from  very  productive 
investigators and consortia at Imperial College London  led to it having  multiple  meanings. Today 
“metabolomics” is: a household word, a society, a journal (Metabolomics, Springer), an FDA entity 
(Center for Metabolomics, Division of Systems Toxicology, NCTR) and an NIH Roadmap Initiative. Its 
primary methodologies for data acquisition are high-resolution 
1H and 
13C NMR spectroscopy and 
mass spectroscopy,  although additional  spectroscopic  methodologies are also involved. Its primary 
methodologies  for  multivariate  statistical  analysis  includes  the  collection  of  techniques  known  as 
SIMCA—Soft Independent Modeling of Class Analogy, which involves hierarchical cluster analysis, 
principal  components  analysis,  different  types  of  partial  least  squares  analysis,  and  subsequent 
modeling with new regression algorithms. 
2.2. Oxidative Stress Comes from Excited Electrons that Provide the Chemical Energy for Life 
The metabolic energy in living systems comes mostly from harnessing excitation energy that was 
transferred to electrons during photochemical or chemical interactions. At the molecular level living 
systems  capture  excited  electron  energy  in  electron  transport  systems  (ETS),  which  for  aerobic Int. J. Mol. Sci. 2011, 12  6472 
 
metabolism  are  located  in  inner  mitochondrial  membrane  protein  assemblies.  Electron  energy  is 
harnessed along their cascade to oxygen, the ultimate electron acceptor in  living cells. Except for 
fluorine, which is minimally present in live entities, oxygen has the highest affinity for electrons. Why 
do  plants  and  animals  need  to  use  complex  electron  transport  systems  to  capture  energy  for 
metabolism?  The  answer,  no  doubt,  was  given  by  Thaddeus  Dobzhansky  (1973)  when  he  wrote, 
“Nothing in biology makes sense except in the light of evolution”. Indeed, electron transport chains for 
biological  energy  extraction  are  known  to  have  been  in  single  cell  systems  since  early  evolution, 
billions of years ago [19,20]. Such seems quite reasonable because of “the Photoelectric Effect”, the 
basic physics phenomenon in which light dislodges a bound atomic electron, giving it energy to move 
to a higher energy orbit or escape. Nobel Prizes in physics for understanding the Photoelectric Effect 
went to Heinrich Hertz, who discovered the effect in 1887, and to Albert Einstein, who fully explained 
it in 1905. In early evolution, when single-cell life began in the oceans, the sun’s rays, beating down 
relentlessly and generating unimaginably large numbers of dislodged electrons, gave full Darwinian 
advantage to systems that could capture some or all of the enormous chemical energy provided by the 
sun to excited electrons. 
3. Reactive Oxygen Species and Oxidative Stress 
The orbital properties of oxygen’s electrons account for its reactive properties as a radical.  An 
understanding  of  that  began  with  Michael  Faraday’s  discovery  in  the  1840’s  that  oxygen  is 
paramagnetic (attracted into a magnet.) However, it was not until 1925,  after quantum  mechanics 
became  more  widely  appreciated,  that  the  mechanism  was  fully  understood.  Robert  Mulliken 
explained it by noting that in its lowest energy state, molecular oxygen has two unpaired electrons. 
Each electron has an intrinsic angular momentum, or spin, of ½, meaning that in a magnetic field it has 
only two quantum states (a doublet): along the magnetic field and opposite to it. Together the spin 
angular momentum of oxygen’s two unpaired, spin ½ electrons, which are in different orbits, add up to 
a spin angular momentum of 1, which in quantum mechanics is a triplet state. Triplet oxygen is the 
lowest energy state of molecular oxygen, and is the normal, commonly existing state. There is also an 
excited orbital state in which the two normally unpaired electrons become paired in the same orbit, 
with one spin aligned opposite to the other, producing spin 0, which is a singlet. This excited and 
potent but short-lived oxidant state is known as singlet oxygen. A molecule with an unpaired electron 
is a radical—except for free molecular oxygen, O2! Radicals are highly reactive chemically. If oxygen 
within a molecule has an unpaired electron, that molecule is known as an oxygen radical. Reactive 
oxygen  species  (ROS)  are  chemically-reactive  molecules  containing  oxygen,  such  as  hydrogen 
peroxide (H2O2) and the hydroxyl free radical (HO·). Oxygen’s extremely high affinity for electrons 
can also allow it to take on an extra electron to form the superoxide anion radical O2
−·, which is also 
an  ROS  molecule.  Henceforth  we  will  denote O2
−·  by  the  shortened term  “superoxide”.  In  living 
systems  there  is  a  constant  formation  of  oxygen  radicals,  along  with  a  system  of  reactions  that 
constantly consumes them. When cells or organisms produce oxygen radicals at a greater rate than 
they  can  be  consumed  by  the  intracellular  systems  built  for  that  purpose,  there  is  a  condition  of 
oxidative stress, and a concern that there will be harmful ROS effects. Int. J. Mol. Sci. 2011, 12  6473 
 
In mitochondrial oxidative phosphorylation the final chemical reaction produced by the electron 
transport chain is 
NADH + ½O2 + H
+  H2O + NAD
+ + energy   
Atomic oxygen collects 2 electrons here, with the basic reaction being 
2H
+ + 2e
− + ½O2  H2O + energy   
which can be appreciated in the first equation from knowing that an early step in the electron transport 
chain was 
NADH  NAD
+ + H
+ + 2e
−   
The “energy” produced in the reaction occurs as a proton gradient across the inner mitochondrial 
membrane, and is used in the phosphorylation reaction that produces ATP. 
It is inevitable that the substrates in the high rate basic reaction will sometimes produce superoxide, 
where the reaction is 
e
− + O2  O2
−   
Evolution has produced key antioxidant enzymes and scavengers to deal with this, the primary ones 
being: superoxide dismutase, which exists in different forms in mitochondria and the cytosol; catalase, 
which is present primarily in peroxisomes; and glutathione peroxidase, which is found both in the 
cytosol and in mitochondria. Superoxide dismutase catalyzes 
2O2
−·+ 2H
+  H2O2 + O2   
while catalase catalyzes 
2H2O2  O2 + 2H2O   
Glutathione is a tripeptide consisting of cysteine, glycine, and glutamate. It exists in reduced (GSH) 
and oxidized (GSSG) states and catalyzes the decomposition of H2O2 and organic peroxides: 
XOOH + 2GSH  GSSG +XOH + H2O   
Although glutathione, along with SOD are the major intracellular antioxidants, the major blood 
plasma  antioxidants  are  uric  acid,  vitamin  C  (ascorbate),  vitamin  E  (-tocopherol),  thiols,  and   
bilirubin [21]. Uric acid is produced during purine degradation by xanthine oxidase from xanthine and 
hypoxanthine. Increased uric acid levels are common during hypoxia and ischemia, and are a marker 
for oxidative stress [21]. 
An  important  additional  path  for  superoxide  damage  was  appreciated  after  it  was  discovered   
that  the  messenger  molecule  responsible  for  vasodilation,  initially  known  as  EDRF 
(Endothelium-Dependent Relaxation Factor), could be identified as nitric oxide (NO) [22]). The nitric 
oxide radical NO combines with superoxide to form peroxynitrite [23]. 
NO + O2
−  ONOO
−   
which  among  its  many  reactions  produces  the  lasting  marker  nitrotyrosine  [24,25].  Nitric  oxide 
together  with  radicals  derived  from  its  reactions  with  either  superoxide  or  oxygen,  are  known Int. J. Mol. Sci. 2011, 12  6474 
 
collectively as reactive nitrogen species (RNS) [26]). Because they often act together, RNS are as 
much a concern as ROS in oxidative stress [27]. 
During physiological increases in metabolism,  for example during exercise, increases in oxygen 
consumption increases the production of oxidants that can produce damage, such as that coming from 
muscular fatigue after strenuous exercise. Protective radical scavenging is accomplished not only by 
reactions  just  described,  but  also  by  scavenging  by  many  other  naturally  present  compounds  that 
contain keto-carbonyl and/or rings, such as vitamin E, vitamin C, and many TCA Cycle metabolites. 
Although  radical  damage  is  the  topic  of  this  review,  it  should  not  be  forgotten  that  excessive 
antioxidant  activity  might  be  disadvantageous  to  organisms  if  it  interferes  with  mechanisms  of 
recovery  and  adaptation.  For  example,  in  ischemic  preconditioning,  transient  increases  in  reactive 
oxygen species can provide protection, which in turn can be blocked by antioxidants [28]. Given all of 
the above, it is easy to see that perturbations of metabolite distributions can result from oxidative 
stress, oxidative damage, and even from antioxidant therapy. Thus it is appropriate to use multivariate 
metabolomics analysis techniques to assess and categorize oxidative protection, injury, and recovery. 
4. Investigations of Two Metabolites as Treatments in Oxidative Stress 
4.1. Fructose-1,6-bisphosphate 
In  1980  Dr.  A.K.  Markov  and  collaborators  published  the  first  of  two  decades  of  manuscripts 
written by his group and others about treating hypoxia, ischemia, or oxidative stress with exogenously 
administered fructose-1-6-bisphosphate (FBP, see Figure 1). In the decades before the year 2000, FBP 
was  sometimes  referred  to  as  FDP,  “fructose  diphosphate”,  which  is  inconsistent  with  chemistry 
nomenclature, as the latter requires that the phosphates be adjacent when using “diphosphate”. This 
point can be important when searching the literature. Markov’s early work [29,30] described in vivo 
and  in  vitro  preclinical  experiments  in  which  FBP  improved  physiological  functions  and  ATP 
preservation during and after periods of oxygen deprivation. The use of exogenous FBP was motivated 
by a clever idea. The authors reasoned that in hypoxia and ischemia, anaerobic glycolysis might be 
suppressed  or  shut  down  if  there  were  not  enough  ATP  available  early  in  glycolysis  for 
phosphorylation of fructose-6-phosphate, and/or also if the acidosis of hypoxia would, additionally, 
excessively  inhibit  the  enzyme  that  is  involved:  phosphofructokinase  (PFK).  They  reasoned  that 
substrate  entry  into  glycolysis  of  one  exogenously  provided  FBP  molecule  would,  compared  to 
substrate entry of one glucose molecule, spare the expenditure of two ATP’s (spent on glucose by 
hexokinase and phosphofructokinase). Using FBP instead of glucose as a glycolytic substrate would 
thus yield four ATP’s per substrate molecule instead of two. Markov et al. administered FBP during 
different circumstances of oxygen deprivation. Dramatic improvements in myocardial function and 
survival  were  seen  [30],  and  the  general  conclusion  arrived  at  by  these  investigators  was  that 
“exogenous  FBP  will  restore  the  activity  of  glycolysis,  which  has  been  inhibited  by  acidosis,  by 
intervening in the Embden-Meyerhoff pathway, both as a metabolic regulator and as a high-energy 
substrate”. At around the same time dramatic findings were also being found by others [31] in a study 
where hypoxic FBP-treated rabbits breathed for an average of 21 min after the initiation of 4% FIO2 
hypoxia, with all being resuscitated after cardiac arrest, compared to glucose treated rabbits breathing Int. J. Mol. Sci. 2011, 12  6475 
 
for an average of only 1.4 min, with only a ≈20% success in resuscitation after cardiac arrest. FBP was 
also  found  to  be  protective  in  focal  cerebral  ischemia,  whether  it  was  given  both  before  or  after 
occlusion, or after reperfusion [32]. As well it was found protective in hypoxia studies with astrocyte 
cultures [33,34] and cerebrovascular endothelial cultures [35]. 
Figure  1.  Schematic  diagram  of  the  chemical  structure  of  Fructose-1,6-Bisphosphate 
(FBP). Two negatively charged phosphate groups (carbons 1 and 6) make it possible for 
FBP to chelate calcium. 
 
Dr. Markov’s work on FBP protection has continued over many years, with publications appearing 
as recently as 2007 [36,37]. During the twenty years that followed his initial FBP experiments, many 
others,  too  many  to  report,  studied  FBP  use  in  hypoxia,  ischemia,  and/or  oxidative  stress.   
Post-ischemic outcome improvements were found by some to be dramatic, by others to be simply 
modest  [38–40],  and  by  a  smaller  number  to  be  completely  nonexistent  [41–43].  Although  many 
important, significant, animal investigations of FBP’s protective and therapeutic actions have been 
carried out since the 1980’s, and although much has also been learned about molecular mechanisms of 
hypoxic/ischemic injury, the mechanisms by which FBP protects various tissues were never clearly 
established,  and  FBP  administration  never  became  part  of  routine  clinical  care.  Still,  many  have 
maintained  that  the  successful  FBP  studies  posed  a  formidable  intellectual  challenge:  could  the 
improved outcomes associated with FBP administration be explained by important, already known, 
injurious mechanisms? For example, in brain ischemia typical mechanisms that are suggested include 
glutamate excitotoxicity, calcium overload, acidosis, oxygen radicals, PARP-1 activation, apoptosis. 
The  challenging  question  is:  are  there  or  are  there  not  new,  important,  undiscovered  protective 
molecular mechanisms that the successful FBP treatments are trying to reveal? 
Many studies have in their discussions that “alternative hypotheses of FBP protection have included 
calcium chelation, free-radical scavenging, and protease inhibition”. In recent years numerous studies 
have pointed to radical scavenging as FBP’s primary protective mechanism [44–46]. An antioxidant 
hypothesis fits well with other recent work that has emphasized that strong antioxidant protection is 
provided by the keto-carbonyl groups that are found in numerous metabolic intermediates. These are 
alleged to confer strong antioxidant properties via peroxidative decarboxylation, which allows -keto 
acids (R-CO-COO
−) to scavenge H2O2 radicals. For example, in the case of pyruvate, R is CH3, and 
the products of the reaction are acetate and the formate radical, with the latter easily converting to   
H2O  +  CO2.  Such  scavenging  is  preferable,  for  example,  to  superoxide  removal  by  superoxide Int. J. Mol. Sci. 2011, 12  6476 
 
dismutase,  which  consumes  two  H
+  ions  that  could  be  used  by  ATPase  to  generate  ATP  [47]. 
Interesting experiments in which DNA  injury  has  lead to PARP-1 activation and NAD
+ depletion, 
which is very bad for sustaining glycolysis, have hypothesized, and then found true, that after PARP-1 
activation  cells  can  be  rescued  by  exogenous  administration  of  TCA  Cycle  intermediates  such  as 
pyruvate and -ketoglutarate [48,49]. In those rescue studies the motivation for administering pyruvate 
and  -ketoglutarate  was  to  provide  the  TCA  Cycle  with  substrates  distal  to  glycolysis,  thereby 
boosting ATP production in a manner reminiscent of Dr. Markov's original motivation. Curiously, 
other researchers were publishing papers at the same time that the above mentioned FBP studies were 
being  done,  but  where  the  use  of    TCA  substrates  were  recommended  because  of  their 
antioxidant properties, not because of TCA Cycle substrate properties [50–54]. 
4.2. Pyruvate 
Pyruvate is able to directly, non-enzymatically accomplish radical scavenging, as mentioned earlier 
with regard to the way peroxides are neutralized. This raises the question: which mechanism is more 
important when rescuing cells by providing metabolic substrates that bypass glycolysis and directly 
feed  the  TCA  Cycle:  the  metabolic  help  that  the  substrates  provide  in  sustaining  ATP,  or  the 
substrates’ antioxidant properties? For example, it is possible in experimental situations where PARP-1 
activation has been proven to occur, to detect decreased NAD
+ and decreased cytosolic glycolysis, and 
then perform a rescue with exogenous administration of pyruvate and other TCA Cycle substrates. In 
experimental  investigations  of  this,  rescue  does  not  occur  if  glucose  is  used.  With 
13C  NMR 
spectroscopy it is also possible, using 
13C-enriched TCA substrates, to detect the TCA metabolism of 
those administered substrates that cause the rescue. To address the question just posed about which is 
more important, we changed the protocol of a previously completed study, and redid the experiments, 
so as to compare two oxidative stress rescue protocols [55]. In the first protocol we tried the rescue by 
adding a nonmetabolizable antioxidant radical scavenger, PBN, to the external medium. In the second 
protocol  we  added  a  metabolizable  TCA  substrate,  ethyl  pyruvate,  to  the  external  medium.  The 
structures of pyruvate and ethyl pyruvate are compared in Figure 2. Ethyl pyruvate easily enters cells 
and efficiently delivers pyruvate to the cytosol. The result in the particular protocol and experimental 
situation  that  was  studied  was  that  the  nonmetabolizable  antioxidant  provided  the  same  ATP 
protection as the addition of the metabolic substrate. In a mouse model of Parkinson’s disease ethyl 
pyrvate  provided  neuroprotection  by  suppressing  astroglial  myeloperoxidase  expression,  NADPH   
oxidase-,  and/or  inducible  NO-synthase-  derived  reactive  oxygen  species/reactive  nitrogen  species 
production  [56].  Other  evidence  of  the  antioxidative  effects  of  pyruvate  include  the  inhibition  by 
topically  or orally  administrated  pyruvate of  the  formation  of  cataracts  induced  by  photochemical 
generation of reactive oxygen species [57,58]. An NMR-based metabolomic study supported a model 
in which the long lifespan of slcf-1 mutants relies on increased mitochondrial pyruvate metabolism 
coupled  to  an  adaptive  response  to  oxidative  stress  [59].  The  above  experiments  illustrated  the 
potential importance of antioxidant actions by metabolites, and also suggest that the mechanism of 
protection and help provided by exogenously administered FBP, which does not significantly enter 
many types of healthy cells, might well be based in its antioxidant properties. Int. J. Mol. Sci. 2011, 12  6477 
 
Figure  2.  Schematic  diagram  of  the  chemical  structures  of  pyruvate  (A)  and  ethyl   
pyruvate (B). Ethyl pyruvate is formed by an ester linkage of pyruvate (right side of the 
structure in Figure 2B) with ethanol (left side of the structure in Figure 2B). 
 
As was summarized in a review of heart experiments [60], pyruvate can protect via mechanisms 
that do not directly involve PARP-1 reactions. Excess pyruvate drives the pyruvate carboxylase (PC) 
and/or  malic  enzyme  reactions  towards  the  formation  of  increased  mitochondrial  citrate.  Citrate 
effluxes to the cytosol where it increases NADPH formation by two mechanisms: (1) suppression of 
PFK activity which causes diversion of glucose-6-phosphate into PPP; and (2) generation of isocitrate 
substrate for converting NADP
+ into NADPH via isocitrate dehydrogenase. Increases in NADPH and 
reducing  equivalents  bolster  GSH  restoration  from  GSSG.  The  increased  ratio  of  GSH/GSSG  in 
pyruvate-enriched cardioplegia has been found to dampen the myocardial inflammation induced by 
oxidative stress [61]. Figure 3 presents a schematic diagram of chemical reactions in oxidative stress. 
Some  studies  found  that  pyruvate  has  other  antioxidant  mechanisms,  such  as  the  up-regulation  of 
glutathione peroxidase mRNA levels [62], the activation of different anti-apoptotic pathways [62], and 
suppression  of  mitochondria  DNA  damage  and  protein  degradation  [63].  By  comparison, 
administration  of  lactate,  which  some  investigators  have  found  to  be  an  important  fuel  for  the   
brain [64–66], did not prevent brain energy depletion in a rodent model with a severe diffuse traumatic 
brain injury (TBI) [67]. The issue of lactate vs. pyruvate as an energy source for neurons has not been 
fully clarified. It has been conjectured that increased synaptic activity stimulates glial metabolism and 
production of lactate that can be consumed by neurons [64,68] but simultaneously increased neuronal 
metabolism of glucose and lactate is probably not possible [65,66]. Int. J. Mol. Sci. 2011, 12  6478 
 
Figure 3. Several key reactions are shown that depict the antioxidant roles of pyruvate and 
FBP. Hydrogen peroxide and peroxynitrite, shown at the top of the diagram, are reactive 
oxygen and nitrogen species formed during oxidative stress. One antioxidant mechanism of 
pyruvate  is  associated  with  the  keto-carbonyl  group  that  can  scavenge  peroxides  and 
peroxynitrites in direct decarboxylation reactions. The antioxidant role of keto-carbonyl 
groups  in  metabolites  would  help  relieve  the  free  radical  burden  handled  by  the  GSH 
system.  Pyruvate  can  indirectly  help  maintain  reduced  glutathione  (GSH)  instead  of 
oxidized glutathione (GSSG) by increasing NADPH production. Pyruvate carboxylation by 
pyruvate carboxylase (PC) and/or malic enzyme (ME) increases the formation of citrate, 
which can  suppress phosphofructokinase (PFK) activity,  and drive glucose-6-phosphate 
into the hexose monophosphate pathway (HMP); or it can generate isocitrate, the substrate 
for NADP
+-dependent isocitrate dehydrogenase (ICDH). 
 
5. The Mechanics of Metabolomics 
The front end of all metabolomics projects is accurate data acquisition. All approaches work best 
when optimum state-of-the-art techniques are use to obtain high signal-to-noise data in which different 
metabolites appear precisely in the same spectral location with identical characteristics. This is often 
not trivial, as many NMR resonance peaks shift with pH, and LC/MS or LC/NMR peaks also shift 
from chromatography changes. With changes in time or circumstance, metabolites in a data set very 
commonly  exhibit  large  variations  in  their  absolute  concentrations,  with  biological  relevance Int. J. Mol. Sci. 2011, 12  6479 
 
sometimes being more in the percentage variation rather than in having the largest absolute value. For 
all of these reasons preprocessing is commonly performed in which data variables are centered and 
scaled with the methods deemed most appropriate in each situation. One approach (Pareto scaling) sets 
the  mean  value  of  each  variable  as  the  zero  reference,  and  then  scales  magnitudes  into  standard 
deviation  units.  However,  there  are  many  other  available  approaches,  such  as  logarithmic  or 
exponential scaling [69]. Appropriate quality controls must be established by investigators for each 
type of data acquisition and processing. 
The next step in metabolomic analyses is the application of pattern recognition algorithms that find 
statistical  differences  and  attach  them  to  distinct  biological  phenomena.  The  “omics”  approach 
generated popularity for certain basic algorithms found in many commercial software packages. Two 
distinct approaches have been established for processing NMR spectra, as outlined in Figure 4. In the 
first,  known  as  chemometrics,  no  attempt  is  made  to  identify  specific  metabolites  in  the  spectra. 
Spectral patterns and intensities are statistically compared somewhat as in a fingerprint analysis. Axes 
for variables are divided into “bins”, or short intervals, and intensities for each bin are the statistical 
variables that are analyzed so as to identify relevant spectral features that will distinguish different data 
sets.  After  grouping  data  sets  according  to  their  differences,  hopefully  with  the  result  being  that 
different  classes  are  very  distinct,  one  then  invokes  one  or  more  approaches  for  identifying  and 
quantifying  the  many  metabolite  concentrations  prominent  for  each  group  [70,71].  In  the  second 
approach to NMR spectral analysis, known as targeted profiling [1,72], the first job is identifying and 
quantifying  each  metabolite  in  every  NMR  spectrum,  so  that  metabolite  concentrations  are  the 
variables, and the next step can be to use “omics”-based statistical methods to search for meaningful 
differences among them. In targeted profiling one must have a priori knowledge of each metabolite’s 
complete NMR spectrum, which means knowing the spectral location and relative signal intensity for 
every 
1H  in  each  metabolite.  The  advantages  of  each  method  have  been  compared  [72,73].  With 
chemometrics one makes no assumptions about the identity and quantity of metabolites in the spectra, 
and,  with  statistical  significance,  one  separates  the  spectra  into  different  groups.  This  is  a  very 
appropriate and efficient approach to large data samples where metabolite compositions and quantities 
might be very different. Thus chemometrics is more easily performed, but its results are less easily 
translated  into harder into clinical or  mechanistic significance. In targeted profiling one quantifies 
specific metabolites and distinguishes spectra based on these. Thus targeted profiling is tedious and 
more slowly accomplished. In situations where the chemical composition of the sample is known, 
quantifications use information about the entire shape of a metabolite peak, and, depending on spectral 
circumstances,  will  provide  more  accurate  or  less  accurate  metabolite  quantifications.    There  are 
different approaches to targeted profiling. One approach that has been used  for many  years  is the 
Linear Combination Model (LC Model), where one finds the best fit to the shape of an NMR spectrum 
by assuming that it is a linear combination of known spectral lineshapes, each being from a particular 
metabolite [74]. Interactive fitting via computer software is a more modern method [72]. Int. J. Mol. Sci. 2011, 12  6480 
 
Figure  4.  Schematic  diagram  showing  alternate  analysis  paths  in  NMR-based 
metabolomics analyses. One begins with 
1H NMR spectra similar to the one at the top of 
the figure, obtained at the NIH-supported Central California 900 MHz NMR Facility at UC 
Berkeley during a study of rat brain extracts. The 
1H resonance for water at 4.66 ppm has 
been removed. The chemical  shifts of  most metabolites  measured in vivo and  in  many 
studies of extracts are typically to the right of 4.66 ppm (upfield), but 
1H nuclei on many 
important  compounds,  such  as  ATP  and  NADH,  are  found  to  the  left  of  4.66  ppm 
(downfield). In the first step of NMR metabolomics, accurate high resolution spectra such 
as the one shown are obtained from solutions containing processed biological fluids or 
tissues from clinic or laboratory sources. As explained in the text NMR spectra are then 
typically  compared  by  one  or  both  of  two  approaches:  chemometrics  and  targeted 
profiling.  In  each  of  the  approaches  it  is  common  to  perform  unsupervised  Principal 
Component  Analysis  (PCA),  and  supervised  Projection  to  Least  Squares-Discriminant 
Analyses (PLS-DA), and each produces Scores Plots and Loading Plots, as explained in 
the text, and exemplified in the bottom part of the figure, where data from three treatment 
groups cluster apart from each other, and metabolites that led to separations are found in 
corresponding quadrants of the Loadings Plot. 
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The basic principle behind “omics” methods, which were made practical by the evolution of fast, 
powerful computers with large data storage capacity, is its being based on a geometrical approach. One 
copes with having a large number of biomarkers or predictors for one subject by considering the entire 
set of numbers as the coordinates of a single point in a multidimensional space. So, if one has 200 
different metabolites measured for one biological sample, or gene expression quantifications for 2000 
genes from one sample, for metabolomic analyses that sample is represented by a single point in a 200 
dimensional space for metabolomics, while for genomic analysis it is represented by a single point in a 
2000 dimensional space. If in the multidimensional space one plots data sets for two different groups, 
for example from two groups of patients where each group had a different treatment for the same 
condition,  then  the  distribution  of  points  for  each  of  the  two  groups  will,  within  statistical  error, 
overlap in every single plane or line that one passes through the space. If however, a plane can be 
found  where  projections  to  the  plane  for  one  treatment  group  has  a  cluster  that  is  significantly 
separated from a cluster in the other treatment group, then a difference exists that can be modeled by 
the acquisition of a lot more data. The general process here is known as SIMCA, or Soft Independent 
Modeling of Class Analogy. And orthogonal directions through the point distributions where variance 
is maximal are known as Principal Component Axes. Usually the number of axes that will sustain 
variance differences between two groups is very much less than the number of biomarkers. Often two 
or three principal component axes are sufficient, but even if the number is larger, the dimension of the 
space  where  variations  appear  is  much  less  than  the  number  of  biomarkers,  200  or  2000  in  the 
examples we cited. 
There are two general types of pattern recognition algorithms in multivariate statistical analyses: 
unsupervised and supervised. The most common unsupervised method, Principal Component Analysis 
(PCA) is usually employed first even if one goes on to complex algorithms with supervised analyses. 
In unsupervised analyses all variables are treated as random, even though some variables might be 
strongly dependent on others. In supervised analyses one uses prior information to make two groups of 
variables: predictors, usually denoted as X, and response variables, usually denoted by Y. The point is 
to test how data in X determine the behavior of data in Y. Many different algorithms are available, 
with common ones being PLS-DA (Projection to Least Squares-Discriminant Analyses; often with the 
words  before  “DA”  being  “Projection  to  Latent  Systems”),  DPLS  (Discriminant  Partial  Least 
Squares), and more. 
For all algorithms two-dimensional Scores Plots are used to display the clusters in planes where the 
x and y axes are Principal Component axes, and the (x,y) coordinates of a data point comes from 
projecting the multidimensional vector for that point onto the plane of the chosen Principal Component 
axes. In the PLS-DA, for example, one algorithm sharpens the PCA clusters and their separations by 
creating a new Y variable for each data class [75]. The Scores Plots in the PCA and PLS-DA analyses 
have corresponding Loadings Plots that identify the metabolites that contributed most to separations in 
the Scores Plot. Like in the Scores Plot, points plotted on the Loadings Plot come from projecting 
multidimensional  vectors  onto  the  plane  of  chosen  Principal  Component  axes.  Each  point  on  a 
Loadings Plot corresponds to a single metabolite, because the vectors projected onto the chosen plane 
are the component vectors along each dimension that added to make the single vector that represents 
the full data set. As an example, an NMR data set of fifty metabolites would contribute one point to a 
Scores Plot, and fifty points to a Loadings Plot. The construction of a model via SIMCA methods Int. J. Mol. Sci. 2011, 12  6482 
 
requires the acquisition of training data sets that define the geometrical attributes of different classes in 
the multidimensional space. When different classes have large separations in a Principal Component 
subspace, the model can be used to predict the likelihood that new data will belong to a particular 
class. A recent T-Cell study provided a good example [76]. 
Recent advances in 
1H NMR data acquisition methods have led to more accurate quantifications of 
NMR-detectable  metabolites.  Of  special  note  is  the  refined  technique  of  Two-Dimensional 
1H   
J-resolved  (JRES)  NMR  Spectroscopy  [77,78].  J-coupling,  which  arises  from  the  magnetic  field 
property of particles that have spin, is the indirect coupling between two chemically bound nuclear 
spins that occurs via the electrons of their chemical bond. In 2D JRES NMR Spectroscopy, the two 
dimensions into which metabolite signals are separated are: one by chemical shift (usually indicated in 
ppm units), and a second one by the magnitude of the J-coupling to neighboring protons (usually in 
units of Hertz). Analogous to when a bar magnet is placed in a magnetic field, a spin ½ nucleus such 
as 
1H or 
13C can exist in either a low energy or high energy state, depending on whether it is aligned 
with or against the main (or applied) magnetic field, which is constant for a given spectrometer, with 
the field strength being somewhere between 7 and 22 Tesla. Which energy state that a nucleus, a 
proton  for  example,  is  in  influences,  to  a  very  small  but  measurable  degree,  the  magnetic  field 
experienced by the electrons responsible for chemical bonds, and ultimately by adjacent protons. For 
the simple case of two protons separated by three bonds, each proton resonance, instead of being a 
singlet peak, will be split into two peaks, i.e., into a doublet, due to the fact that the other proton can be 
in one of two states. The separation in Hertz between the two signals in the doublet is referred to as the 
J-coupling. It is independent of the strength of the applied magnetic field, because it is determined 
only by the difference in the magnetic field at one nucleus that is experienced by an orientation change 
in another nucleus. J-coupling can exist between 
1H nuclei on adjacent carbons, for example between 
the methyl protons on lactate and the 
1H proton on the center carbon (C2), or between 
1H nuclei and 
adjacent or  nearby 
13C  nuclei.  The 
1H–
1H  J-coupling  in  lactate  is  approximately  7  Hz,  while  the 
1H–
13C  J-coupling  between  the  lactate’s  methyl  protons  (on  C3)  and 
13C  in  [3-
13C]  lactate  is 
approximately 128 Hz. For the rest of this discussion we will be referring only to 
1H-
1H J-coupling. 
The phenomenon of J-coupling is used to separate the 
1H signals into a second dimension in the 2D 
JRES experiment, as illustrated in Figure 5. In Figure 5 it is also apparent that the 2D separation of the 
resonances helps resolve signals that overlap in normal 1D 
1H spectra. For metabolomics studies, a 2D 
1H JRES spectrum can be fit directly. The choice of NMR data acquisition parameters for a 2D 
1H 
JRES  spectrum  permits  the  extraction  of  a  1D 
1H  spectrum  from  the  2D  dataset  in  which  the   
J-couplings have been removed. This is because the 1D 
1H spectrum is obtained by projecting the 2D 
data straight down onto the horizontal 
1H axis, and  in the 2D data set, the data in the J-coupling 
dimension are vertically aligned. Thus for any particular 
1H resonance, data for all J-couplings appear 
in the projected 1D JRES spectrum at the same ppm. Removal of J-coupling information from 1D 
1H 
spectra in this way reduces the overlap of resonance peaks from different metabolites, and allows more 
accurate metabolite quantifications. Improvements in the identification and quantification of glutamate 
and  glutamine  are  particularly  impressive,  as  seen  in  Figure  5  and  Figure  4.  Other  impressive 
comparisons and elucidations can be found in papers by Viant et al [79] and Ludwig and Viant [78]. 
The notation 1D 
1H pJRES, which is popular among certain authors, is used to refer to the 
1H spectrum 
produced by projecting a 2D 
1H JRES spectrum onto the 
1H axis. The 2D 
1H JRES and 1D 
1H pJRES Int. J. Mol. Sci. 2011, 12  6483 
 
approaches are likely to become widely used, as such data can be recorded quickly (~20 min), and 1D 
and 2D spectra are easy to process and analyze.   
Figure  5.  Typical  900  MHz  NMR  spectra  for  2D 
1H  JRES  and  1D 
1H  pJRES 
spectroscopy. (A) The 
1H lactate resonance at 1.33 ppm, which comes from the methyl 
group on lactate’s middle carbon, provides a good example of the differences that occur in 
JRES spectroscopy. Because of 
1H-
1H J-coupling between methyl 
1H nuclei and the 
1H 
atom on the other side of the methyl group, the 
1H lactate doublet at 1.33, which has its 
two peaks separated by 7 Hz or 0.008 ppm, as can be seen in the 2D plot and the black 1D 
standard spectrum at the top of the figure. In the downwards projection of the 2D plot onto 
the x-axis, which creates the 1D pJRES spectrum, the 7 Hz doublet merges to form a sharp 
singlet. There is no lateral dispersion of a nucleus’ NMR signal when one projects the 2D 
spectrum down onto the ppm axis, because the J-coupling data were aligned vertically. 
This produces 1D 
1H NMR spectra in which metabolites have less overlap with each other; 
(B) A comparison is provided between a standard 1D 
1H spectrum (bottom of the two 
spectra) and a 1D 
1H pJRES spectrum (upper of the two spectra). The numbers refer as 
follows to the metabolites: 1. Isoleucine; 2. Leucine; 3. Valine; 4. Lactate 
13C; 5. Lactate; 
6. Alanine; 7. Alanine 
13C; 8. Acetate 
13C; 9. GABA; 10. Acetate; 11. NAA; 12. NAAG; 
13. Glutamate; 14. Glutamate/Glutamine; 15. Succinate; 16. Glutamine. The baseline is 
clearly  much  flatter,  and  ripples  caused  by 
1H-
1H  J-coupling  are  very  much  reduced. 
Glutamate and glutamine (peaks 13 and 14), which are difficult to quantify in normal 1D 
spectra, are collapsed into sharp peaks in 1D 
1H JRES Spectroscopy. Note that when the 
methyl carbon of lactate is a 
13C nucleus, one still has the 
1H-
13C J-coupling that produces 
the satellite lactate peaks approximately 0.07 ppm to either side of 1.33 ppm. The 
1H-
13C 
coupling is not collapsed with this type of JRES spectroscopy; (C) An expanded view of 
the glutamate-glutamine region permits better appreciation of the improvement created by 
JRES Spectroscopy. 
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Figure 5. Cont. 
 
Other 2D NMR methods that have been used in metabolomics studies include 
1H-TOCSY [80] and 
1H-
13C HSQC experiments [81,82]. An advanced 2D NMR technique, known as Targeted Projection 
NMR Spectroscopy [70] can be used when overlapping signals hamper analysis of TOCSY and HSQC 
spectra. In this method, a “tilted” 2D projection of a hybrid 3D TOCSY-HSQC spectrum is recorded. 
The projection can be tailored to resolve specific overlapping sets of resonances [83]. A highly cited 
2008 publication by Gowda and colleagues reviewed many NMR experiments available to develop 
diagnoses from metabolic profiles [84]. 
6. Brain Metabolomics and Oxidative Stress 
6.1. Schizophrenia   
Schizophrenia, a complex mental disorder of variable onset that usually develops between the ages 
of 10 and 40, is characterized by cognitive challenges. It is devastating for those afflicted, who can 
suffer from any or all of several difficulties, such as thinking logically, differentiating between real and 
unreal experiences, and having normal emotional responses. It is present in approximately 1.1% of all 
societies regardless of class, ethnicity, religion, or culture, with new cases per year being approximately   
1  in  4000,  and  in  the  top  10  causes  of  disability  in  developed  countries  [85].  Neurological 
investigations point to a “disconnect hypothesis” that occurs over a long period within the brain’s Int. J. Mol. Sci. 2011, 12  6485 
 
ongoing remodeling of synapses [86]. Neurons that loose synaptic connections can undergo apoptosis, 
a type of noninflammatory cell death that might account for reductions in brain tissue that have been 
detected in the relevant frontal cortical areas of schizophrenic patients [87,88]. At the molecular level, 
impaired antioxidant defenses system and oxidative stress have for a long time been known to be part 
of the pathophysiology. The very recent review by Yao and Reddy [89] discusses many publications 
providing  evidence  from  biochemistry,  proteomics  [90],  genetics  [91],  in  vivo  brain  imaging,  and 
metabolomics [92,93] that point to derangements in redox signaling. The very comprehensive review 
by  Prabakaran  et  al.  used  both  proteomics  and  metabolomics  of  fresh,  pre-frontal  brain  tissue  to 
convincingly identify differences in oxidative stress enzymes and metabolites between schizophrenic 
and  non-schizophrenic  patients  [92].  Although  there  is  no  cure  for  schizophrenia  at  this  time, 
substantial improvements from treatments are possible, and approaches to antioxidant therapy, while 
likely to have an important role, need considerable more research [94]. 
6.2. Neonatal Asphyxia   
Research in neonatal asphyxia is a very active area because of some very positive findings in large, 
recent clinical trials that have studied mild therapeutic hypothermia (brain temperature decrease of   
4° C) treatments immediately after birth [95–98]. Some but not all neonates have greatly improved 
long term neurological outcomes. Mild hypothermia treatments have not been beneficial to the adult 
brain  immediately  after  traumatic  brain  injury  or  stroke  [99–101],  despite  there  being  substantial 
benefits to the adult heart from mild hypothermia after cardiac ischemia [102–105]. A metabolomic 
investigation of urine in neonates who suffered asphyxia found that elevated urinary organic acids 
were significantly associated with good and poor neurodevelopmental outcome, and that they were 
related to oxidative stress [106]. In a metabolomics study of urine using 
1H NMR spectroscopy in a 
piglet preclinical model of neonatal asphyxia, metabolic variations were found that were associated 
with  hypoxia  levels,  with  group  discriminations  primarily  due  to  differences  in  urea,  creatinine, 
malonate, methylguanidine, hydroxyisobutyric acid [107]. In a rodent brain slice model of neonatal 
ischemia, a metabolomics approach based on 
1H/
31P NMR spectroscopy of perchloric acid brain tissue 
extracts found that after recovery from injurious oxygen-glucose deprivation (OGD), final ATP levels 
were severely decreased in a normothermia group, but had recovered to equally to control values after 
mild hypothermia treatments that began either before OGD or a delay time after it. However, cell 
death  at the  end  of the  experiments  was  decreased  in  the  immediate  hypothermia  group,  but  was 
equally substantially greater with in the normothermia and delayed hypothermia groups. The Scores 
Plots in the metabolomics PCA and PLS-DA analyses clearly separated the three groups. Potentially 
important biomarkers  in the 
1H spectra  included PCr, ATP and ADP (all of which were resolved 
thanks  to  very  high  spectral  resolution),  and  were  supportive  of  future  potential  roles  for  brain 
metabolomic monitoring during therapeutic hypothermia [108]. 
6.3. Parkinson’s Disease   
Parkinson’s disease, whose major signs are tremor, rigidity, and impaired body movement, is a 
neurodegenerative  disorder  of  unknown  cause  that  affects  million  of  older  people,  decreases  life 
expectancy and quality, and is expected in this century to surpass cancer as the second most common Int. J. Mol. Sci. 2011, 12  6486 
 
cause  of  death  among  the  elderly  [109,110].  Oxidative  stress  has  been  strongly  implicated  in  its 
pathophysiology  [47].  The  development  of  biomarkers  and  medications  is  of  great  importance, 
because early diagnosis, which is very difficult from clinical signs alone, can greatly improve patient 
management. Metabolomic profiling, by identifying blood markers of DNA damage along with reduced 
uric acid and greatly increased glutathione, has also implied a strong role for oxidative stress [111]. 
Attempts at combined proteomics/metabolomics have shown substantial promise [112,113]. 
6.4. Traumatic Brain Injury 
Traumatic brain injury (TBI) was investigated in a rodent model with high resolution 
1H NMR 
metabolomics studies of brain tissue extracts and plasma at 11.7 Tesla [114]. Regional brain metabolite 
decreases in ascorbate, and changes in other metabolites showed clear evidence of oxidative stress and 
excitotoxic  brain  damage.  Significant  TBI-associated  changes  in  overall  spectral  patterns  were 
demonstrated  in  principal  components  analysis  of  brain  tissue  extracts,  but  no  clear  effects  were 
discerned in NMR spectra of plasma. In the other two studies of TBI, oxidative stress is demonstrated 
by  a  decrease  in  anti-oxidative  reserves  (e.g.,  ascorbate,  GSH,  and  protein  sulfhydrls)  [115]  and 
increases in excitatory amino acids [116]. 
7. Diabetes and Kidney-Metabolomics and Oxidative Stress 
In  the  early  1990’s  it  was  appreciated  that  increased  oxidative  stress  is  important  in  the 
pathophysiology of diabetes, because the protein glycosylation that occurs during long exposures to 
hyperglycemia leads to free radical production [117–119]. In diabetic patients, increases in oxidative 
damage to lipids and proteins correlates with the increases in complications of the disease [21,119]. 
A recent 9.4 Tesla 
1H-NMR metabolomic investigation of diabetic retinopathy in humans used a 
chemometric  approach  with  PCA  and  PLS-DA  analysis  to  show  that  spectra  for  vitreous  humor 
samples  clearly  separated  diabetic  patients  from  non-diabetic  patients.  Among  14  very  clearly 
distinguished  metabolites,  decreased  ascorbate  and  increased  galactitol  were  the  main  biomarker 
changes for diabetic retinopathy, although increased lactate and glucose were found in samples from 
all diabetics [120]. The decrease in ascorbate was attributed to higher consumption from higher levels 
of oxidative stress. A recent preclinical study of diabetes used a streptozotocin rat model to study urine 
and plasma metabolomics with 
1H NMR at 11.75 Tesla [121]. Spectra were analyzed with chemometrics 
and profiling that identified 17 metabolites. Plasma TBARS (thiobarbituric acid-reacting substances) 
were quantified as a measure of oxidative stress. Diabetic rats had altered metabolic pathways and 
augmented fat degradation products caused by free radicals. 
With regard to metabolomic investigations of oxidative stress in the kidney, one human study, in 
which it was known a priori that cyclosporine nephrotoxicity initially occurs in the proximal tubule, 
somewhat driven by increased formation of oxygen radicals, found that metabolomics measures with 
1H-NMR and HPLC-MS are sensitive enough to detect toxicity as soon as 4 h after a single oral dose, 
and  could  serve  as  a  tool  for  clinical  diagnoses  [122].  Several  rodent  studies  used  similar 
metabolomics methods to detect and quantify oxidative stress in the kidney from ischemia/reperfusion 
injury  [123],  radiation  injury  [124],  and  drug  toxicities  for  acetaminophen  [125],  cinnabar  [126], 
fenofibrate [127], and ochratoxin [128]. Int. J. Mol. Sci. 2011, 12  6487 
 
8. Liver Metabolomics-Metabolomics and Oxidative Stress 
Two very recent liver metabolomics studies provided data on oxidative stress in humans. In the   
first [129], plasma profiles in patients were studied for three pathological conditions: nonalcoholic 
fatty  liver disease,  steatosis, and steatohepatitis. Metabolomic data could separate healthy subjects 
from those with fatty liver disease with an error rate of approximately 8% and separate those with 
steatohepatitis from healthy controls with an error rate of 4%. However, metabolomics data could not 
separate patients with hepatic steatosis from those with steatohepatitis. Marked changes in bile salts 
and glutathione-related biochemicals were identified in the different group, and a panel of biomarkers 
was found that can potentially be used to follow response to therapeutic interventions. 
In liver transplantation one first causes oxidative stress by inducing ischemia during organ removal 
from  the  donor,  and  then  one  causes  oxidative  stress  by  reoxygenation  and  perfusion  after organ 
implantation in the recipient. Thus hepatotoxicity in liver transplantation acutely involves considerable 
oxidative stress. In a very recent human study of 8 liver transplant patients [130], consecutive biopsy 
findings included that metabolomics time-profiles demonstrated considerable changes in redox-active 
metabolites up until 18 h postreperfusion, after which there was stabilization. Metabolomics data came 
from Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FT-ICR MS) of liver biopsy 
tissue,  and  also  from  microdialysates  of  extracellular  fluid  by  coulometric  electrochemical  array 
detection (CEAD). FT-ICR MS reproducibly detected more than 4,000 peaks, revealing hundreds of 
significant metabolic differences between pre- and postreperfusion grafts.   
In the literature of preclinical experiments there were numerous studies  in rodents that showed 
distinct  associations  between  metabolomic  data  and  experimental  manipulations.  For  example, 
deficiency  of  -tocopheral  was  studied  [131],  as  were  hepato-  and  nephron-toxicants  [132],   
obesity [133], and acetaminophen toxicity [134]. 
One important function of the liver is to detoxify poisons that come into an organism, especially via 
the  gastrointestinal  system.  Xenobiotics  are  chemicals  found  in  organisms  that  are  not  normally 
produced or expected to be present. The high importance of being able to recognize toxins motivated 
the  formation  by  certain  leaders  in  metabonomics  research  of  The  Consortium  for  Metabonomic 
Toxicology  (COMET),  which  is  between  five  major  pharmaceutical  companies  and  The  Imperial 
College of London [135]. This group has assessed methodologies and used rodent urine and blood to 
generate a 
1H NMR metabonomic database for use in evaluating and dealing with xenobiotic toxicity. 
9. Cardiac and Vascular Metabolomics and Oxidative Stress 
Investigations with human tissues and fluids included a LC-MS (liquid chromatography and mass 
spectroscopy) metabolomics study of plasma lipids that was done for 14 patients having documented 
silent myocardial ischemia (SMI), as compared to 25 matched control patients [136]. Scores Plots in 
the  multivariate  statistic  analysis  showed  a  clear  separation  between  the  two  studied  groups. 
Plasma concentrations  of  four  phospholipids  had  a  tight  association  with  SMI,  with 
1-linoleoylglycerophosphocholine (C18:2) being significantly decreased in the SMI group, suggesting 
that such measurements might facilitate early diagnosis. A careful metabolomics study of hypoxia in 
humans  [137],  motivated  by  the  deleterious  roles  hypoxia  plays  in  cardiovascular  disorders  and Int. J. Mol. Sci. 2011, 12  6488 
 
numerous  diseases,  looked  for  evidence  of  oxidative  stress,  and  also  for  evidence  that  HIF,   
hypoxia-inducible transcription factor, is activated in vivo in humans during hypoxia. The group used a 
hypobaric chamber to expose fourteen human subjects to normoxia corresponding to an altitude of 
1600 meters, and to hypoxia corresponding to an altitude of 4300 m (alveolar PO2 ≈ 48 mm Hg).   
HIF-1 DNA binding and HIF-1α protein were evaluated in circulating leukocytes, and several markers 
of  oxidative  stress  were  among  47  metabolites  studied  with 
1H  NMR  plasma  metabolomics. 
Circulating glutathione was reduced by 35% (p = 0.001), and lactate and succinate were increased by 
29 and 158%, respectively (p = 0.007 and 0.001), as were urinary 15-F2t-isoprostanes (p = 0.037), 
showing that hypoxia causes substantial increases in plasma and urinary markers of oxidative stress. 
Another metabolomics study in humans [138] used LC-MS to look for oxidative stress in the etiology 
of abdominal aortic aneurysms (AAA), the 13th leading cause of death in the United States with up to 
9,000 deaths annually. An AAA is a permanent, localized aortic dilation greater than 3 cm in diameter. 
AAA  enlargement  occurs  irregularly,  and  pathology  of  the  involved  vascular  tissue  has  been 
associated previously with oxidative stress,  chronic  inflammation,  elastin  fragmentation, apoptosis, 
loss of extracellular matrix, neovascularization, and a depletion of smooth muscle cells. Metabolites 
were compared that came from different portions of human aortic aneurysms--luminal and abluminal 
layers, aneurysm walls, and healthy walls. Compounds related to inflammation and oxidative stress 
were found, as was a possible role of fatty acid amides. Some metabolites (e.g., hippuric acid) had not 
been previously associated with such aneurysms. 
Several  recent  animal  studies  have  used  metabolomics  to  investigate  oxidative  stress  in 
cardiovascular systems. Complementary to the human data just cited are proteomic and metabolomic 
analyses of atherosclerotic vessels from apolipoprotein E-deficient mice that revealed alterations in 
inflammation, oxidative stress, and energy metabolism [139] Oxidative stress in atherogenesis was 
apparent in that study from the upregulation of numerous antioxidant proteins the detection of ROS 
protein damage, and the increase in albumin degradation. Damage was found in enzymes susceptible 
to free radical inactivation, including aconitase, cytochrome C reductase, and the Rieske protein of 
ubiquinol. Such damage can release free iron, thereby promoting subsequent formation of hydroxyl 
radicals,  and  perpetuating  oxidative  stress,  as  explained  early  in  the  review.  Proteomic  and 
metabolomics  measures  were  made  in  a  dog  model  for  congestive  heart  failure  and  ventricular 
tachycardia, with the heart paced at 240 beats per min for 24 h in one group, and for 2 weeks in 
another  [140].  Oxidant  stress  was  evident  in  the  24  h  group  from  the  substantial  decrease  in 
antioxidant proteins, including SOD and peroxiredoxin. Heat shock protein increases and other protein 
changes were analyzed, as was the metabolic stress related to congestive heart failure (CHF). That 
study provided insights to the arrhythmogenic atrial remodeling that results from such physiological 
stress. In an initial study by others of mice deficient in protein kinase C delta [141], proteomic and 
metabolomics  analysis  of  smooth  muscle  cells  demonstrated that  loss  of  PKC  delta  improved  the 
cellular  redox  state  by  elevating  GSH  levels,  and  thus  provided  protection  against  oxidative   
stress-induced cell death. However, in a second study with mice deficient in protein kinase C delta [28], 
they  showed  that  the  loss  of  PKC  delta  caused  the  loss  of  protection  provided  by  ischemic 
preconditioning, because transient increases in reactive oxygen species cause preconditioning, while 
antioxidants block the beneficial effects of preconditioning. The two studies, besides adding useful   
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specific  biochemical  information,  provide  a  good  example  of  a  general  point  made  earlier,  that 
antioxidant augmentation is not good in situations where it impairs host defenses. 
10. Cancer Metabolomics and Oxidative Stress 
Metabolic derangements and adaptations by cancers have recently been carefully reviewed [142], 
with  two  prominent  features  being:  (1)  excess  glucose  metabolism  and  lactate  production  with 
avoidance of the TCA cycle, even in the presence of substantial oxygen availability [Warburg Effect]; 
and  (2)  mitochondrial  malfunction  with  augmented  ROS  production.  The  role  of  ROS  in  tumor 
progression  is  controversial,  because  increased  ROS  can  serve  what  might  appear  to  be  opposite 
functions, namely induction of apoptosis, or augmentation of mutagenesis and tumor proliferation. 
Apoptosis can also be induced by radiation therapy of tumors. Indeed, radiation toxicity is attributed to 
the increased oxidative stress triggered by direct ionization of biological polymers and the generation 
of  reactive  oxygen  species  via  radiolysis  of  water,  which  produces  hydroxyl  radicals  [143].  In 
radiation  therapy,  however, there  are  adaptive  responses.  A  study  of  22  metabolites  from  healthy 
human leukocytes that had radiation exposures of 2 Gy, 4 Gy and 8 Gy found that relative to control 
data at 0 Gy, metabolites were substantially depleted at 2 Gy and 8 Gy, but substantially upregulated at 
4 Gy, with many at values greater than control. A recent review [144] discussed metabolomics and 
oxidative stress in pheochromocytomas, endocrine cell tumors that come from chromaffin cells in the 
adrenal medulla and can produce enormous amounts of catecholamines. 
11. Conclusions 
A  wide  variety  of  publications  were  found  that  make  important  clinical  and  mechanistic 
associations between oxidative stress and specific metabolites, metabolite groups, and metabolomics 
analyses.  Table  A1  provides  a  compendium  of  associations  between  pathological  situations  with 
oxidative stress, and metabolites identified in particular studies, all of which are cited in the list of 
references.  Included  in  the  table  are  references  to  six  publications  [145–150]  that  had  valuable 
information, but matched more than one the categories we established, and were not referenced earlier.   
Complex relationships connect oxidative stress to many physiological processes. It is hoped that by 
developing  multivariate analyses techniques  it will  be able to discern characteristics of  metabolite 
ensembles that distinguish different physiological processes, and in so doing, be able to learn key 
mechanistic aspects and also develop useful interventions. The goal of studying the metabolomics of 
oxidative stress is to develop methods that serve as a tool for diagnoses, treatment guidance, and drug 
discovery. The rapid pace of research in this area gives hope for such progress. 
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Appendix 
Table A1. Metabolomic studies in different diseases associated with oxidative stress. 
Pathology  Change of metabolites  Samples 
Analytical 
technique  Ref.  Year 
CNS           
Schizophrenia  Taurine ; Glutathione  Prefrontal cortex tissue 
from patients 
1H NMR  [92]  2004 
Schizophrenia  Glucose ; Acetate ; Alanine; Glutamine    CSF from human 
1H NMR  [145]  2006 
Schizophrenia  Phosphotidylethanolamine  
Phosphotidylcholine  
Lipid extracts of patient's 
plasma 
HPLC  [146]  2007 
Parkinson's disease  Uric acid ; GSSG   Plasma from patients  LCECA  [111]  2008 
Parkinson's disease  Urate   Plasma from patients  LCECA  [147]  2009 
Trauma Brain Injury  Ascorbate ; Glutamate ; NAA ; Total of PC/GPC     Brain tissue extracts and 
plasma from rats 
1H NMR  [114]  2005 
Asphyxia  Glutarate ; Methylmalonate ; 3-hyroxy-butyrate ; Orotate   Urine from patients  MS  [106]  2006 
Hypoxia-reoxygenati
on 
Urea; Creatinine; Malonate; Methylguanidine; Hydrooxyisobutyric acid  Urine from piglets 1–4 
days old 
1H NMR  [107]  2010 
Oxygen-Glucose 
deprivation 
PCr; ATP ; NAA; Taurine  Rat brain slice extracts 
1H/
31P NMR  [108]  2011 
           
Diabetes and Renal diseases         
Proliferative diabetic 
retinopathy   
Ascorbate ; Galactitol   Vitreous samples from 
patients 
1H NMR  [120]  2010 
Type 1 diabetes  Glucose ; Alanine ; Lactate ; Ethanol ; Acetate ; Fumarate   Urine and plasma from rats   
1H NMR  [148]  2008 
Cyclosporine 
nephrotoxicity 
15-F(2t)-isoprostane ; Creatinine ; Citrate ; Hippurate ; Phenylalanine  Urine and plasma from 
human 
1H NMR 
HPLC-MS 
[122]  2010 
Kidney 
transplantation 
Allantoin ; Polyunsaturated fatty acids   Kidney tissue and plasma 
from rats 
1H NMR  [123]  2005 
Radiation injury  Glyoxylate ; Threonate ; Thymine ; Uracil ; Citrate ; Adipate ; 
Pimelate ; Suberate ; 2-oxoglutarate  
Urine from rats  GC-MS  [124]  2009 
Ochratoxin A toxicity  2-oxoglutarate ; Citrate ; Glucose ; Creatinine ; Pseudouridine ; 
5-oxoproline ; Myo-inositol  
Urine from rats  GC-MS 
1H NMR 
LC-MS 
[128]  2009 Int. J. Mol. Sci. 2011, 12  6501 
 
Table A1. Cont. 
Pathology  Change of metabolites  Samples 
Analytical 
technique  Ref.  Year 
Cisplatin-induced 
nephrotoxicity 
Glucosuria ; Nonesterified fatty acids ; Triglycerides   Kidney tissue, urine, 
plasma from rats 
1H NMR  [149]  2007 
           
Cardiovascular diseases         
Hypoxia  Glutathione ; Lactate ; Succinate 
 
Plasma and urine from 
human 
1H NMR  [137]  2009 
Abdominal aortic 
aneurysms 
Fatty acid amides  Aortas tissue from human  LC-MS  [138]  2011 
Atherosclerosis  Alanine ; 1-Cys peroxiredoxin (identified in proteomics)  Mouse aortas tissue   
1H NMR  [139]  2005 
H2O2-induced stress  Alanine ; Lactate ; Carnitine ; Glutathione  Mouse C2C12 myotubes  MS  [141]  2004 
Doxorubicin 
cardiotoxicity 
Acetate ; Succinate   Dog heart tissue extracts 
1H NMR  [150]  2009 
           
Hepatic diseases         
Fatty liver disease 
Steatohepatitis 
Glycocholate; Taurocholate 
 
Carnitine; Butyrylcarnitine; Cysteine/Glutathione 
Plasma from patients  GC-MS  [129]  2011 
Acetaminophen-induc
ed hepatotoxicity 
Ophthalmate   Mouse liver extracts and 
serum 
CE-TOFMS  [134]  2006 
Obesity  Hepatic ratios of PUFA/MUFA  Glutathione     Liver lipid extracts and 
serum from rat 
1H NMR  [133]  2006 
           
Cancer           
Ionizing radiation  Arginine ; Glutamine ; Creatine ; Proline ; GSH  Human leukocytes  CE-ESI-MS  [143]  2010 
           
LCECA: Liquid chromatography coupled with eletrochemical coulometric array; GC-MS: Gas chromatography-mass spectrometry; LC-MS: Liquid chromatography-mass 
spectrometry; CE-TOFMS: Capillary eletrophoresis time-of-flight mass spectrometry; CE-ESI-MS: Capillary electrophoresis mass spectrometry. 
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